Quantifying the under-estimation of cervical Cancer in remote regions of Tanzania.
Cervical cancer
Epidemiology
Expected
Incidence
Observed
Tanzania
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
30 Sep 2020
30 Sep 2020
Historique:
received:
07
04
2020
accepted:
20
09
2020
entrez:
1
10
2020
pubmed:
2
10
2020
medline:
15
4
2021
Statut:
epublish
Résumé
Cervical cancer is the most common cancer among women in Sub-Saharan countries, including Tanzania. While early detection and diagnosis are available in some parts of this large country, radiotherapy has been only available at the Ocean Road Cancer Institute (ORCI), in the capital city of Dar es Salaam and is just starting in a few regions. The objective of this study was to compare the observed incidence of cervical cancer for the two remote regions of Mwanza in western Tanzania and Mbeya in southern Tanzania, based on their patients treated at the ORCI from 2011 to 2014. The number patients referred and treated at ORCI were (120 from Mwanza, and 171 from Mbeya, representing 24.6 and 32.8% of the patients histopathologically confirmed in the two sites, respectively. The results showed significant underestimation of cervical cancer in the two regions. The vast majority of patients who were histopathologically-confirmed in their local regions (73.92% from Mwanza and 65.1% from Mbeya), but did not receive the needed radiotherapy treatment at the ORCI. The estimated incidence for the two regions based on the number of patients treated at the ORCI were underestimated by 53.9% for Mwanza and 68.9% for Mbeya. Local establishment of radiotherapy treatment facilities in remote regions in Tanzania and similar other low-income countries is essential for providing effective treatment and improving survival of diagnosed cervical cancer patients. Linkage between the records of local remote hospitals and the main cancer treatment center in the capital city can also help support the emerging the population-based cancer registry at ORCI.
Sections du résumé
BACKGROUND
BACKGROUND
Cervical cancer is the most common cancer among women in Sub-Saharan countries, including Tanzania. While early detection and diagnosis are available in some parts of this large country, radiotherapy has been only available at the Ocean Road Cancer Institute (ORCI), in the capital city of Dar es Salaam and is just starting in a few regions.
METHODS
METHODS
The objective of this study was to compare the observed incidence of cervical cancer for the two remote regions of Mwanza in western Tanzania and Mbeya in southern Tanzania, based on their patients treated at the ORCI from 2011 to 2014.
RESULTS
RESULTS
The number patients referred and treated at ORCI were (120 from Mwanza, and 171 from Mbeya, representing 24.6 and 32.8% of the patients histopathologically confirmed in the two sites, respectively. The results showed significant underestimation of cervical cancer in the two regions. The vast majority of patients who were histopathologically-confirmed in their local regions (73.92% from Mwanza and 65.1% from Mbeya), but did not receive the needed radiotherapy treatment at the ORCI. The estimated incidence for the two regions based on the number of patients treated at the ORCI were underestimated by 53.9% for Mwanza and 68.9% for Mbeya.
CONCLUSIONS
CONCLUSIONS
Local establishment of radiotherapy treatment facilities in remote regions in Tanzania and similar other low-income countries is essential for providing effective treatment and improving survival of diagnosed cervical cancer patients. Linkage between the records of local remote hospitals and the main cancer treatment center in the capital city can also help support the emerging the population-based cancer registry at ORCI.
Identifiants
pubmed: 32998702
doi: 10.1186/s12885-020-07439-3
pii: 10.1186/s12885-020-07439-3
pmc: PMC7526175
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
939Subventions
Organisme : NCI NIH HHS
ID : R25 CA112383
Pays : United States
Références
Int J Gynaecol Obstet. 2011 Apr;113(1):14-24
pubmed: 21257169
Lancet Glob Health. 2019 Jan;7(1):e20-e21
pubmed: 30514615
Crit Rev Oncol Hematol. 2013 Mar;85(3):303-14
pubmed: 22883215
Int J Gynaecol Obstet. 2013 Dec;123(3):221-5
pubmed: 24095307
J Glob Oncol. 2019 Jul;5:JGO1800052
pubmed: 31343933
Int J Chronic Dis. 2018 May 2;2018:2458232
pubmed: 29854721
Int J STD AIDS. 2016 Oct;27(12):1049-1056
pubmed: 26464500
Int J Gynecol Cancer. 2015 Jan;25(1):98-105
pubmed: 25423318